SAHA

Biological Activity

SAHA inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro. Activates autophagy. SAHA increases efficiency of transcription factor-induced reprogramming of mouse embryonic fibroblasts (MEF) to induced pluripotent stem cells (iPSC). Also enhances adeno-associated virus transduction of HeLa cells.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
   Leoni et al.
   Proc.Natl.Acad.Sci.U.S.A, 2002;99:2995
2. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
   Marks and Breslow
   Nat.Biotechnol., 2007;25:84
3. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds.
   Huangfu et al.
   Nat.Biotechnol., 2008;26:795
4. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.
   Galluzzi et al.
   Nat.Rev.Drug.Discov., 2017;
5. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
   Butler et al.
   Cancer Res., 2000;60:5165
6. Identification and validation of small molecules that enhance recombinant adeno-associated virus transduction following high-throughput screens.
   Nicolson et al.
   J.Virol., 2016;90:7019

Product Datasheets